PPMD Applauds FDA for Approval of AGAMREE® (Vamorolone) for Duchenne Patients Ages Two Years and Older streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pompe Disease Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Leading Companies - Asklepios Biopharmaceutical, Inc., Astellas Pharma Inc., Amicus Therapeutics, Sanofi, Spark Therapeutics lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
By Ben Glickman Catalyst Pharmaceuticals said that it would commercially launch Agamree, a treatment for Duchenne Muscular Dystrophy, after the treatment was approved by the U.S. Food and Drug.
/PRNewswire/ Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), welcomed.